Primary Central Nervous System Lymphoma (PCNSL) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2022 To 2032
Primary Central Nervous System Lymphoma (PCNSL) is an aggressive type of non-Hodgkin lymphoma localized to the CNS, including the brain, spine, CSF, and eyes. Most PCNSL cases are diffuse large B-cell lymphoma, while Burkitt, low-grade, or T-cell lymphomas are rare. Neurological symptoms usually appear gradually over several weeks, including changes in mental status, behavioral changes, focal neurologic deficits, and symptoms of increased intracranial pressure, such as headaches, nausea, vomiting, papilledema, and seizures, depending on the site of CNS involvement. To determine the severity of the disease, the International PCNSL Collaborative Group suggests conducting baseline staging, which includes magnetic resonance imaging of the brain (and spine if spinal symptoms are present), ophthalmologic evaluation, and CSF evaluation. Patients with primary refractory or relapsed PCNSL face a grim prognosis, with a median survival rate of only two months without additional treatment. PCNSL is rare in immunocompetent patients and accounts for only 4% of all intracranial neoplasms and 4% to 6% of all extranodal lymphomas, primarily in patients over 60 years old, with an incidence rate of 0.5 per 100,000 annually.
· In the United States, around 1,500 new cases are diagnosed each year.
Thelansis’s “Primary Central Nervous System Lymphoma (PCNSL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Central Nervous System Lymphoma (PCNSL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Primary Central Nervous System Lymphoma (PCNSL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Primary Central Nervous System Lymphoma (PCNSL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
